AstraZeneca says US trial data shows vaccine 79% effective

AstraZeneca says US trial data shows vaccine 79% effective
AP
Share
Font Size
Save
Comment
Synopsis

The U.S. study comprised 30,000 volunteers, 20,000 of whom were given the vaccine while the rest got dummy shots. The results were announed Monday.

Reuters
Phase three trials involving more than 32,000 volunteers across all age groups, conducted in the U.S., Chile and Peru have shown that COVID-19 AstraZeneca vaccine is safe and highly effective, the University of Oxford said on Monday.
says advanced trial data from a U.S. study on its COVID vaccine shows it is 79% effective.

The U.S. study comprised 30,000 volunteers, 20,000 of whom were given the vaccine while the rest got dummy shots. The results were announed Monday.

The early findings from the U.S. study are just one set of information AstraZeneca must submit to the Food and Drug Administration. An FDA advisory committee will publicly debate the evidence behind the shots before the agency decides whether to allow emergency use of the vaccine.

While the AstraZeneca vaccine has been authorized in more than 50 countries worldwide, scientists have been awaiting results of the U.S. study in hopes it will clear up some of the confusion about just how well the shots really work.

Read More News on

(Catch all the Business News, Breaking News Events and Latest News Updates on The Economic Times.)

Download The Economic Times News App to get Daily Market Updates & Live Business News.

Read before you invest. Insights on AstraZeneca Pharma India Ltd.. Explore Now